# Antiaging Properties of the Klotho Protein

**Authors:** Gérald J. Prud’homme, Qinghua Wang

PMC · DOI: 10.3390/cells15060507 · 2026-03-12

## TL;DR

The Klotho protein helps slow aging by reducing inflammation, protecting cells, and preventing age-related diseases.

## Contribution

This paper identifies Klotho as a key antiaging protein that mitigates multiple aging hallmarks and age-related diseases.

## Key findings

- Klotho improves mitochondrial function and reduces ROS, telomere attrition, and cellular senescence.
- Klotho inhibits inflammation via NF-κB and NLRP3, benefiting conditions like atherosclerosis and Alzheimer’s.
- Low Klotho levels cause hyperphosphatemia and cell injury, while Klotho mitigates fibrosis and sarcopenia.

## Abstract

Mice genetically deficient in α-Klotho (henceforth Klotho) display accelerated aging. The mechanisms are only partially understood. Here, we examine how these relate to the 12 hallmarks of aging consisting of chronic inflammation (inflammaging), as well as damaging changes to the genome (DNA damage), telomeres, epigenetic regulation, proteostasis, nutrient sensing, mitochondria, stem cells, intercellular communication, macroautophagy, microbiome and cell replication (senescence). Inflammation aggravates the other hallmarks. We report that Klotho counters the majority of these hallmarks. It ameliorates mitochondrial function and reduces reactive oxygen species (ROS), telomere attrition and cellular senescence. It protects against inflammation by inhibiting NF-κB and the NLRP3 inflammasome. This applies to inflammaging, several chronic inflammatory diseases, atherosclerosis, diabetes, and Alzheimer’s disease. Klotho also counters some aging factors outside of these hallmarks. Low Klotho (often due to kidney disease) produces hyperphosphatemia, which injures cells (especially endothelial cells) and promotes aging. Another key action of Klotho is the mitigation of fibrosis in major organs (kidneys, heart, lungs and other), mainly through the inhibition of TGF-β and Wnt. Klotho also protects against muscle atrophy (sarcopenia)—a common feature of aging—and exhibits anti-cancer activity. We describe several factors that increase Klotho, and are potentially amenable to clinical therapy.

## Linked entities

- **Genes:** CG9701 (uncharacterized protein) [NCBI Gene 39872], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], Wnt (protein Wnt-2) [NCBI Gene 100641115]
- **Proteins:** CG9701 (uncharacterized protein)
- **Diseases:** atherosclerosis (MONDO:0005311), diabetes (MONDO:0005015), Alzheimer’s disease (MONDO:0004975), kidney disease (MONDO:0001343)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, NLRP1 (NLR family pyrin domain containing 1) [NCBI Gene 22861] {aka AIADK, CARD7, CIDED, CLR17.1, DEFCAP, DEFCAP-L/S}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, Tgfb2 (transforming growth factor, beta 2) [NCBI Gene 21808] {aka Tgf-beta2, Tgfb-2}, TRPV5 (transient receptor potential cation channel subfamily V member 5) [NCBI Gene 56302] {aka CAT2, ECAC1, OTRPC3}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, Pparg (peroxisome proliferator activated receptor gamma) [NCBI Gene 19016] {aka Nr1c3, PPAR-gamma, PPAR-gamma2, PPARgamma, PPARgamma2}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, Tgfbr1 (transforming growth factor, beta receptor I) [NCBI Gene 21812] {aka ALK5, Alk-5, ESK2, TGFR-1, TbetaR-I, TbetaRI}, Psen1 (presenilin 1) [NCBI Gene 19164] {aka Ad3h, PS-1, PS1, S182}, IKBKG (inhibitor of nuclear factor kappa B kinase regulatory subunit gamma) [NCBI Gene 8517] {aka AMCBX1, EDAID1, FIP-3, FIP3, Fip3p, IKK-gamma}, MEFV (MEFV innate immunity regulator, pyrin) [NCBI Gene 4210] {aka FMF, MEF, PAAND, TRIM20}, NODAL (nodal growth differentiation factor) [NCBI Gene 4838] {aka HTX5}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, NLRC4 (NLR family CARD domain containing 4) [NCBI Gene 58484] {aka AIFEC, CARD12, CLAN, CLAN1, CLANA, CLANB}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, Kl (Klotho) [NCBI Gene 83504], SMAD2 (SMAD family member 2) [NCBI Gene 4087] {aka CHTD8, JV18, JV18-1, LDS6, MADH2, MADR2}, KL (klotho) [NCBI Gene 9365] {aka HFTC3, KLA}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, REL (REL proto-oncogene, NF-kB subunit) [NCBI Gene 5966] {aka C-Rel, HIVEN86A, IMD92}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, TXN (thioredoxin) [NCBI Gene 7295] {aka TRDX, TRX, TRX1, TXN1, Trx80}, Tgfbr2 (transforming growth factor, beta receptor II) [NCBI Gene 21813] {aka 1110020H15Rik, DNIIR, RIIDN, TBR-II, TbetaR-II, TbetaRII}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Mstn (myostatin) [NCBI Gene 17700] {aka Cmpt, Gdf8}, FGFR1 (fibroblast growth factor receptor 1) [NCBI Gene 2260] {aka BFGFR, CD331, CEK, ECCL, FGFBR, FGFR-1}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, RELB (RELB proto-oncogene, NF-kB subunit) [NCBI Gene 5971] {aka I-REL, IMD53, IREL, REL-B}, NFKB2 (nuclear factor kappa B subunit 2) [NCBI Gene 4791] {aka CVID10, H2TF1, LYT-10, LYT10, NF-kB2, p100}, TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, Fgf23 (fibroblast growth factor 23) [NCBI Gene 64654] {aka Fgf8b}, TXNIP (thioredoxin interacting protein) [NCBI Gene 10628] {aka ARRDC6, EST01027, HHCPA78, THIF, VDUP1}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, MYH14 (myosin heavy chain 14) [NCBI Gene 79784] {aka DFNA4, DFNA4A, FP17425, MHC16, MYH17, NMHC II-C}, FGFR4 (fibroblast growth factor receptor 4) [NCBI Gene 2264] {aka CD334, JTK2, TKF}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta) [NCBI Gene 3551] {aka IKK-2, IKK-beta, IKK2, IKKB, IMD15, IMD15A}, Gdf11 (growth differentiation factor 11) [NCBI Gene 14561] {aka BMP-11, Bmp11}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, Adam10 (a disintegrin and metallopeptidase domain 10) [NCBI Gene 11487] {aka 1700031C13Rik, MADM, kuz, kuzbanian}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, AIM2 (absent in melanoma 2) [NCBI Gene 9447] {aka PYHIN4}
- **Diseases:** autoimmune diseases (MESH:D001327), AMD (MESH:D008268), ischemic necrosis (MESH:D005271), blindness (MESH:D001766), vessel occlusion (MESH:C536223), hyperlipidemia (MESH:D006949), loss of muscle mass (MESH:C536030), myocardial infarcts (MESH:D009203), loss of muscle mass and/or function (MESH:D009135), multiple-organ failure (MESH:D009102), acute or chronic kidney failure (MESH:D058186), ventricular hypertrophy (MESH:D024741), Tumor (MESH:D009369), tissue (MESH:D017695), Fibrosis (MESH:D005355), multiple sclerosis (MESH:D009103), endotoxemia (MESH:D019446), Sepsis (MESH:D018805), chronic (MESH:D002908), emphysema (MESH:D004646), Alzheimer's disease (MESH:D000544), hypervitaminosis D. (MESH:D006986), , pancreas, colon and liver (MESH:D017093), necrosis (MESH:D009336), hypertension (MESH:D006973), calcification (MESH:D002114), heart failure (MESH:D006333), infectious diseases (MESH:D003141), hyperglycemia (MESH:D006943), hypercalcemia (MESH:D006934), Chronic inflammation (MESH:D007249), thrombosis (MESH:D013927), FGF23 deficiency (MESH:D006130), advanced renal failure (MESH:D051437), microangiopathy (MESH:D014652), chronic kidney disease (MESH:D051436), hypophosphatemia (MESH:D017674), pulmonary fibrosis (MESH:D011658), cirrhosis of the liver (MESH:D008103), hemorrhage (MESH:D006470), infections (MESH:D007239), septic shock (MESH:D012772), injury to (MESH:D014947), calcification of the aorta and iliac arteries (MESH:D017543), retinal fibrosis (MESH:D012173), occlusion of the middle cerebral artery (MESH:D020244), stroke (MESH:D020521), infarction (MESH:D007238), endothelial injury (MESH:D057772), type 2 diabetes (MESH:D003924), Obesity (MESH:D009765), death (MESH:D003643), bone and dental anomalies (MESH:D001847), kidney disease (MESH:D007674), DR (MESH:D003930), cardiac disease (MESH:D006331), metastasis (MESH:D009362), multi-organ atrophy (MESH:D001284), retinal epithelial-cell degeneration (MESH:D012162), Sarcopenia (MESH:D055948)
- **Chemicals:** Phosphate (MESH:D010710), ROS (MESH:D017382), astaxanthin (MESH:C005948), urate (MESH:D014527), dasatinib (MESH:D000069439), Pi (MESH:D010716), GSH (MESH:D005978), AGEs (MESH:D017127), pentoxifylline (MESH:D010431), SA (MESH:D000077145), carbohydrate (MESH:D002241), losartan (MESH:D019808), metformin (MESH:D008687), ATP (MESH:D000255), Vit D (MESH:D014807), quercetin (MESH:D011794), everolimus (MESH:D000068338), glucose (MESH:D005947), sugars (MESH:D000073893), valsartan (MESH:D000068756), GABA (MESH:D005680), Cholesterol (MESH:D002784), Ca2+ (-), fluvastatin (MESH:D000077340), calcium (MESH:D002118), curcumin (MESH:D003474), atorvastatin (MESH:D000069059), rapamycin (MESH:D020123), 1,25(OH)2D3 (MESH:D002117), resveratrol (MESH:D000077185), alcohol (MESH:D000438), doxorubicin (MESH:D004317), K+ (MESH:D011188), Telmisartan (MESH:D000077333)
- **Species:** Canis lupus familiaris (dog, subspecies) [taxon 9615], Rattus norvegicus (brown rat, species) [taxon 10116], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Somniosus microcephalus (Greenland shark, species) [taxon 191813], Rodentia (rodent, order) [taxon 9989], Felis catus (cat, species) [taxon 9685], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Panax ginseng (Asiatic ginseng, species) [taxon 4054]
- **Mutations:** C370S, F352V, serine/threonine
- **Cell lines:** beta — Gorilla gorilla gorilla (Western lowland gorilla), Transformed cell line (CVCL_R799), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), INS-1 — Rattus norvegicus (Rat), Rat insulinoma, Cancer cell line (CVCL_0352)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024879/full.md

---
Source: https://tomesphere.com/paper/PMC13024879